The Society of Interventional Oncology (SIO) and Boston Scientific have announced a new multicentre, prospective, randomised trial to study combination therapy of radioembolization and immunotherapy in early and intermediate hepatocellular carcinoma (HCC) patients not eligible for curative treatments: ROWAN.
Led by investigators Beau Toskich (Mayo Clinic Florida, USA) and Aiwu Ruth He (Georgetown University Lombardi Comprehensive Cancer Center, USA), ROWAN will evaluate the safety and efficacy of TheraSphere Y-90 glass microspheres (Boston Scientific) administered before initiation of durvalumab with tremelimumab compared to treatment of TheraSPhere alone. The study will assess local tumour control, progression-free survival, and the effect of TheraSphere radiation dosimetry on immune response.
Patient enrollment will begin later this year.
